Scouting report · NTRA
Steven L. Chapman
Joined Natera in 2010 as a sales VP; CEO and President since January 2019
- Born / age
- (46)
- Role
- Chief Executive Officer, President and Director
- In the role
- 8 yr
- Education
- BS University of California, Los Angeles
- Front Office rank
- not ranked yet
NTRA
Natera, Inc.Diagnostics
- Title
- Chief Executive Officer, President and Directorsrc
- In role
- since 2019-01 (8 yr)
Stake value—no holding or price on file
—thin record
Scouting sheetas of 24 Sep 2026
Delivers guidance—no promises on the record yet
Answers the question—no call reviewed yet
Capital allocation—company not reviewed yet
Pay design5550% performance-conditioned · revenue, margin, fcf, time only · 98% for · company lost money
Skin in the game—no holding or price on file
—Hit rate
50%Pay at risk
98%Say-on-pay
—Airtime on calls
- Beat
- 0
- Met
- 0
- Missed
- 0
- Withdrawn
- 0
- Still open
- 0
- Answers on calls
- 0
- Questions dodged
- 0
- Dodges / 100 answers
- —
Personal and ownership data
What to weigh
Watch 5
- Personal defendant in a certified securities class action (Rule 10b-5, class period 2020-02-26 to 2022-03-14). The complaint alleges he, Brophy and Rabinowitz sold stock while holding material non-public information. These are allegations, not findingssrc
- On his watch a jury found Natera liable for false advertising against Guardant Health, with $292.5m of damages (Nov 2024). The court largely upheld the verdict in July 2025 and Natera plans to appeal. A 2022 CareDx false-advertising verdict of $44.9m against Natera was set aside, and the Third Circuit affirmedsrc
- Little skin in the game: 32,401 shares beneficially owned (16,767 held plus 15,634 vesting within 60 days), under 0.1% of the company, after about $94m of stock sales in the last 12 monthssrc
- 2025 bonus target for revenue was set at $1,883.2m, about 11% growth. Actual growth was 35.9%, so the company element paid 131.1%. His bonus is 100% company metricssrc
- Total 2025 pay of $14.96m, a 101:1 CEO pay ratio, in a year the company lost $208.2m under GAAPsrc
Pay
Salary and otherBonus, stock, options, incentive
The table
- Bonus pays on
- Cash incentive at 100% of salary target, 100% on company metrics: revenue 55%, product gross margin 35%, operating cash flow 10%; paid 131.1% for 2025, delivered as fully vested RSUs
- Long-term award pays on
- 50% PSUs vesting on a three-year cumulative revenue goal, 50% time-based RSUs vesting over four yearssrc
- Pay at risk 50% performance-conditioned
- Pays on returns revenue, margin, fcf, time only
- Shareholder vote 98% for
- Pay vs profit company lost money
CEO pay ratio 101 : 1
Career
- 2019 – nowNaterasrc
Chief Executive Officer, President and Director
Appointed effective 2019-01-02 when co-founder Matthew Rabinowitz stepped down as CEO and became Executive Chairman - 2017 – 2019
- 2010 – 2017
- 2003 – 2010
- 2002 – 2003UCLA, Department of Human Geneticssrc
Researcher (first job)
The proxy gives no dates; the years are inferred from the 2002 class year (WS-ucla) and the 2003 Genzyme start
Not located: Title at Genzyme Genetics (2003-2010) not stated in any filing; UCLA research dates inferred, not stated
The promise ledger
No promise on the record yet: the research routine has not scored this company's guidance.
Background
- Family The 2026 proxy states the only family relationship among directors and executive officers is the Rabinowitz brothers. Director Rowan Chapman, who chairs the human capital committee that sets his pay, is therefore not a relative per the proxysrc
- Boards Director of the American Clinical Laboratory Association (ACLA), the lab-industry trade groupsrc
- Other A scientist by training who came up through sales: began as a human-genetics researcher at UCLA, then seven years in the commercial organisation at Genzyme Genetics before Naterasrc
- Legal Named as a defendant, with Natera, Brophy and Rabinowitz, in the securities class action in the Western District of Texas (filed April 2022, amended October 2022) over statements about Prospera and Panorama. The motion to dismiss was granted in part and the court has certified the classsrc
Sources11
- Filing Natera DEF 14A for the 2026-06-11 annual meeting (accession 0001104659-26-047770) · 2026-04-23
- Filing Natera DEF 14A, 2018 (accession 0001047469-18-002528), Executive Officers section · 2018-04-04
- Filing Natera 8-K Item 5.02, Chapman appointed CEO and President; Rabinowitz resigns as CEO (0001104659-19-001251) · 2019-01-08
- Filing Natera 8-K Items 5.02/5.07, 2026 annual meeting results (0001604821-26-000003) · 2026-06-16
- Filing Natera 10-K for FY2025 (0001104659-26-020881), Legal Proceedings note and risk factors · 2026-02-27
- Filing SEC XBRL companyconcept us-gaap/NetIncomeLoss, CIK 1604821 (FY2025 10-K, 0001104659-26-020881) · 2026-02-27
- Filing SEC XBRL companyconcept us-gaap/RevenueFromContractWithCustomerExcludingAssessedTax, CIK 1604821 (FY2018 from 0001558370-21-001907; FY2025 from 0001104659-26-020881) · 2026-02-27
- Filing Form 4, Steven Leonard Chapman (reporting CIK 1711968), 10b5-1 sale of 2026-09-01 (0001711968-26-000022); window totals summed over all 18 of his Form 4s filed 2025-09-29 to 2026-09-03 · 2026-09-03
- Filing Form 4, Steven Leonard Chapman, option exercise and 10b5-1 sale of 2025-11-03 (0001711968-25-000011) · 2025-11-03
- Web search result WebSearch: UCLA Alumni class note 'Steve Chapman '02' (Natera CEO) · 2026-09-24
- Web search result WebSearch: Kessler Topaz case page and amended complaint, Natera securities class action (W.D. Tex. 1:22-cv-00398); names Natera, Steve Chapman, Michael Brophy, Matthew Rabinowitz among defendants · 2026-09-24